Significance of the study:
It has been shown earlier that antagonizing angiotensin II type I receptor (AT1R) expression may prolong mammalian life span. Further, it has been shown that disruption of AT1R (AGTR1) gene results in marked prolongation of mammalian lifespan.
From research findings to therapeutic opportunity:
Figure1. Mechanistic insights into how Kallistatin functions as a longevity- promoter. Kallistatin, by increasing the expression of its downstream target genes, down regulates A1TR expression and promotes longevity.
This study suggests, for the first time, that Kallistatin, by increasing the expression of its target genes, it may decrease the expression of AT1R.
And, thereby, it may: (1) decrease blood pressure; (2) decrease blood sugar levels; (3) inhibit pulmonary fibrosis; (4) enhance bacterial immunity; (5) inhibit myocardial infarction; (6) decelerate ageing process; and (4) extend the lifespan of an individual. Thus, pharmacological formulations encompassing “Kallistatin or its activators, either alone or in combination with other anti-ageing/longevity promoting compounds,“ may be used to extend the lifespan of an individual (Figure 1).
[easy_payment currency=”USD”]
Details of the research findings:
Idea Proposed/Formulated by:
Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Undisclosed mechanistic information: How does Kallistatin suppress the expression of angiotensin II type I receptor (AT1R)?
Amount: $300#
For purchase and payment details, you may reach us at info@genomediscovery.org
# Research cooperation
References:
Citation: Boominathan, L., Lifespan extension therapy: Kallistatin prolongs mammalian life span via down regulation of angiotensin II type I receptor (AT1R), 30/May/2017, 11.03 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Web: http://genomediscovery.org or newbioideas.com/
Courtesy: When you cite drop us a line at info@genomediscovery.org